FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
- Country
- Spain
- Type
- Beneficiary
- Website
- www.vhio.net
- Grants received
- 48
Funding record
- 48 grants on record
- €24,703,575.57 awarded in total
- 2008–2025 span of the record
Grants recorded here are the ones our sources publish, and the total is the sum of those. It is not a statement of this organisation's total funding.
Programmes
- Horizon Europe Framework Programme
- European Research Council
- Seventh Framework Programme
- Horizon 2020 Framework Programme
19 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations this one has been funded alongside on two or more projects. A single shared consortium is not counted: the largest here has 195 members, and being on one list together is not a collaboration.
- STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN
- UNIVERSITA DEGLI STUDI DI TORINO
- DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
- INSTITUT GUSTAVE ROUSSY
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
- EUROPEAN MOLECULAR BIOLOGY LABORATORY
- FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Calls from this organisation
No published calls from this organisation.
Grants received
- Nanoengineered particles for enhanced cancer radiotherapy
- VHIO International postDoctoral programme for translAtional research
- Risk assessment Tools for severe side Effects after breasT Radiotherapy: radiation safety through biological extended models and dIgital twinS
- Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applications
- Maximizing the use of a first clinically viable MYC inhibitor
- AI-BASED PERSONALISED CARE FOR RESPIRATORY DISEASE USING MULTI-MODAL DATA IN PATIENT STRATIFICATION
- MAP, JOIN AND DRIVE EUROPEAN ACTIVITIES FOR ADVANCED THERAPY MEDICINAL PRODUCT DEVELOPMENT AND IMPLEMENTATION FOR PATIENT AND SOCIETY BENEFIT
- A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE SAGITTARIUS TRIAL
- COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
- First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma
- Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors
- Unraveling the Functional Complexity of Cancer Genomes through Chromosome Engineering
- Open Consortium for Decentralized Medical Artificial Intelligence
- CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE
- A Coordination and Support Action to prepare UNCAN.eu platform
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
Retrieved from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.